Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.67 USD | +0.82% |
|
-3.10% | -19.76% |
May. 07 | Sector Update: Health Care Stocks Advance in Late Afternoon Trading | MT |
May. 07 | Surgery Partners Rises after Q1 Adjusted Earnings, Revenue Increase; 2024 Revenue Outlook Boosted | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 35.24 and 25.66 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.30% | 3.22B | C- | ||
-25.47% | 15.13B | B+ | ||
-1.80% | 11.77B | B | ||
+6.18% | 10.36B | B+ | ||
+26.71% | 8.54B | B | ||
-6.29% | 7.42B | A- | ||
+5.59% | 6.72B | B- | ||
+8.59% | 6.32B | D | ||
-2.79% | 4.3B | - | ||
+9.97% | 4.21B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SGRY Stock
- Ratings Surgery Partners, Inc.